Island Pharmaceuticals (ASX:ILA) received a patent from the US Patent and Trademark Office for the use of its antiviral drug, galidesivir, for the potential treatment of filoviridae viruses, including Marburg and Ebola, according to a Wednesday filing with the Australian bourse.

The US patent provides the company with protection to pursue treatment options for viruses from the filoviridae family using galidesivir until Oct. 14, 2031, the filing said.

Shares of the company rose 12% in recent Wednesday trade.